跳转至内容
Merck
CN

45720

毒扁豆碱 水杨酸盐

≥97.0% (N)

别名:

伊色林 水杨酸盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C15H21N3O2 · C7H6O3
化学文摘社编号:
分子量:
413.47
EC Number:
200-343-8
UNSPSC Code:
12352005
PubChem Substance ID:
Beilstein/REAXYS Number:
3900576
MDL number:
Assay:
≥97.0% (N)
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

synthetic

assay

≥97.0% (N)

form

powder

optical activity

[α]20/D −77±2°, c = 1% in ethanol

mp

181-183 °C

SMILES string

OC(=O)c1ccccc1O.CNC(=O)Oc2ccc3N(C)[C@H]4N(C)CC[C@@]4(C)c3c2

InChI

1S/C15H21N3O2.C7H6O3/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2;8-6-4-2-1-3-5(6)7(9)10/h5-6,9,13H,7-8H2,1-4H3,(H,16,19);1-4,8H,(H,9,10)/t13-,15+;/m1./s1

InChI key

HZOTZTANVBDFOF-PBCQUBLHSA-N

Biochem/physiol Actions

乙酰胆碱酯酶抑制剂越过血脑屏障并与乙酰胆碱酯酶形成缓慢降解的氨基甲酰酶络合物。


wgk

WGK 3

pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 2 Oral

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



S Rubnov et al.
Journal of pharmaceutical and biomedical analysis, 18(6), 939-945 (1999-01-30)
A simple stability-indicating HPLC assay has been developed for physostigmine salicylate, capable of following its degradation. A 250 x 5 mm i.d. column packed with 10 microm Bondapak C18 was used, with a mobile phase of acetonitrile - ammonium acetate
D K Lim et al.
Pharmacology, biochemistry, and behavior, 31(3), 627-631 (1988-11-01)
The present study demonstrates that continuous administration with physostigmine salicylate (0.12 or 0.24 mg/kg/hr via mini-osmotic pumps) induces toxicities (e.g., body weight loss, decreased water consumption, tremors, decreased body temperatures, mortality) in guinea pigs. Both blood and brain cholinesterase activity
F H Norris et al.
Clinical pharmacology and therapeutics, 54(6), 680-682 (1993-12-01)
We evaluated a double-blind, placebo-controlled, and double-crossover trial of oral physostigmine salicylate for a 9-month period in 13 of 25 patients with sporadic amyotrophic lateral sclerosis (ALS). A large dropout rate of 48% was secondary to eight deaths and four